A comparison of three treatment strategies in recent onset non-systemic Juvenile Idiopathic Arthritis: Initial 3-months results of the BeSt for Kids-study

Pediatric Rheumatology

Volumn 15, Issue 1, 2017, Pages

  Hissink Muller, P C E ^a,f   Brinkman, D M C ^a,b   Schonenberg, D ^c   Koopman Keemink, Y ^d   Brederije, I C J ^a   Bekkering, W P ^a   Kuijpers, T W ^c   van Rossum, M A J ^e   van Suijlekom Smit, L W A ^f   van den Berg, J M ^c   Allaart, C F ^a   ten Cate, R ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Alrijne Hospital Locatie Leiderdorp Department of Internal Medicine   (Netherlands)

^c UNIVERSITY OF AMSTERDAM   (Netherlands)

^d JULIANA CHILDREN S HOSPITAL   (Netherlands)

^e Amsterdam Rheumatology and Clinical Immunology Center   (Netherlands)

^f SOPHIA CHILDREN S HOSPITAL   (Netherlands)

Author keywords

Biologicals; Inactive disease; Juvenile idiopathic arthritis; Treat to target; Treatment strategy study; Window of opportunity

Indexed keywords

ANTINUCLEAR ANTIBODY; CORTICOSTEROID; ETANERCEPT; METHOTREXATE; PREDNISOLONE; PREDNISONE; SALAZOSULFAPYRIDINE; TRIAMCINOLONE; ANTIRHEUMATIC AGENT;

ACR PEDI30; ACR PEDI50; ACR PEDI70; ARTICLE; BEHAVIOR DISORDER; CARDIOVASCULAR DISEASE; CHAQ SCORE; CHILD; CONTROLLED STUDY; DIARRHEA; DISEASE ACTIVITY SCORE; DRUG DOSE REDUCTION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ERYTHROCYTE SEDIMENTATION RATE; FATIGUE; FEMALE; FEVER; GASTROENTERITIS; HEADACHE; HUMAN; HYPERTRANSAMINASEMIA; INFECTION; INTENTION TO TREAT ANALYSIS; INTERMETHOD COMPARISON; JUVENILE ARTHRITIS DISEASE ACTIVITY SCORE; JUVENILE RHEUMATOID ARTHRITIS; LEUKOPENIA; LUNG DISEASE; MAJOR CLINICAL STUDY; MALAISE; MALE; MUSCULOSKELETAL DISEASE ASSESSMENT; NAUSEA; RANDOMIZED CONTROLLED TRIAL; RECTUM HEMORRHAGE; SCHOOL CHILD; SKIN DISEASE; SKIN INFECTION; SLEEP DISORDER; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION; VISUAL ANALOG SCALE; VOMITING; ARTHRITIS, JUVENILE; CLINICAL TRIAL; COMBINATION DRUG THERAPY; COMPARATIVE STUDY; DRUG ADMINISTRATION; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PRESCHOOL CHILD; SUBCUTANEOUS DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, JUVENILE; CHILD; CHILD, PRESCHOOL; DRUG ADMINISTRATION SCHEDULE; DRUG SUBSTITUTION; DRUG THERAPY, COMBINATION; ETANERCEPT; FEMALE; HUMANS; INJECTIONS, SUBCUTANEOUS; MALE; METHOTREXATE; SULFASALAZINE; TREATMENT OUTCOME;

EID: 85011660223     PISSN: None     EISSN: 15460096     Source Type: Journal    
DOI: 10.1186/s12969-017-0138-4     Document Type: Article

References (31)

1. Prakken B, Albani S, Martini A. Juvenile idiopathic arthritis. Lancet. 2011;377(9783):2138-49.
2. Vastert SJ, Kuis W, Grom AA. Systemic JIA: new developments in the understanding of the pathophysiology and therapy. Best Pract Res Clin Rheumatol. 2009;23(5):655-64.
3. Selvaag AM, Aulie HA, Lilleby V, Flato B. Disease progression into adulthood and predictors of long-term active disease in juvenile idiopathic arthritis. Ann Rheum Dis. 2014.
4. Petty RE, Southwood TR, Baum J, Bhettay E, Glass DN, Manners P, Maldonado-Cocco J, Suarez-Almazor M, Orozco-Alcala J, Prieur AM. Revision of the proposed classification criteria for juvenile idiopathic arthritis: Durban, 1997. J Rheumatol. 1998;25(10):1991-4.
5. Albers HM, Brinkman DM, Kamphuis SS, van Suijlekom-Smit LW, van Rossum MA, Hoppenreijs EP, Girschick HJ, Wouters C, Saurenmann RK, Houwing-Duistermaat JJ, et al. Clinical course and prognostic value of disease activity in the first two years in different subtypes of juvenile idiopathic arthritis. Arthritis Care Res (Hoboken ). 2010;62(2):204-12.
6. Hinze C, Gohar F, Foell D. Management of juvenile idiopathic arthritis: hitting the target. Nat Rev Rheumatol. 2015.
7. Wallace CA. The use of methotrexate in childhood rheumatic diseases. Arthritis Rheum. 1998;41(3):381-91.
8. Lovell DJ, Giannini EH, Reiff A, Cawkwell GD, Silverman ED, Nocton JJ, Stein LD, Gedalia A, Ilowite NT, Wallace CA, et al. Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group. N Engl J Med. 2000;342(11):763-9.
9. Lovell DJ, Reiff A, Ilowite NT, Wallace CA, Chon Y, Lin SL, Baumgartner SW, Giannini EH. Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis. Arthritis Rheum. 2008;58(5):1496-504.
10. Giannini EH, Ilowite NT, Lovell DJ, Wallace CA, Rabinovich CE, Reiff A, Higgins G, Gottlieb B, Singer NG, Chon Y, et al. Long-term safety and effectiveness of etanercept in children with selected categories of juvenile idiopathic arthritis. Arthritis Rheum. 2009;60(9):2794-804.
11. van Rossum MA, van Soesbergen RM, Boers M, Zwinderman AH, Fiselier TJ, Franssen MJ, ten CR, van Suijlekom-Smit LW, Wulffraat NM, van Luijk WH, et al. Long-term outcome of juvenile idiopathic arthritis following a placebo-controlled trial: sustained benefits of early sulfasalazine treatment. Ann Rheum Dis. 2007;66(11):1518-24.
12. Klein A, Kaul I, Foeldvari I, Ganser G, Urban A, Horneff G. Efficacy and safety of oral and parenteral methotrexate therapy in children with juvenile idiopathic arthritis: an observational study with patients from the German Methotrexate Registry. Arthritis Care Res (Hoboken). 2012;64(9):1349-56.
13. Giannini EH, Brewer EJ, Kuzmina N, Shaikov A, Maximov A, Vorontsov I, Fink CW, Newman AJ, Cassidy JT, Zemel LS. Methotrexate in resistant juvenile rheumatoid arthritis. Results of the U.S.A.-U.S.S.R. double-blind, placebo-controlled trial. The Pediatric Rheumatology Collaborative Study Group and The Cooperative Children's Study Group. N Engl J Med. 1992;326(16):1043-9.
14. Giannini EH, Cassidy JT, Brewer EJ, Shaikov A, Maximov A, Kuzmina N. Comparative efficacy and safety of advanced drug therapy in children with juvenile rheumatoid arthritis. Semin Arthritis Rheum. 1993;23(1):34-46.
15. Woo P, Southwood TR, Prieur AM, Dore CJ, Grainger J, David J, Ryder C, Hasson N, Hall A, Lemelle I. Randomized, placebo-controlled, crossover trial of low-dose oral methotrexate in children with extended oligoarticular or systemic arthritis. Arthritis Rheum. 2000;43(8):1849-57.
16. Tynjala P, Vahasalo P, Tarkiainen M, Kroger L, Aalto K, Malin M, Putto-Laurila A, Honkanen V, Lahdenne P. Aggressive combination drug therapy in very early polyarticular juvenile idiopathic arthritis (ACUTE-JIA): a multicentre randomised open-label clinical trial 264. Ann Rheum Dis. 2011;70(9):1605-12.
17. Wallace CA, Giannini EH, Spalding SJ, Hashkes PJ, O'Neil KM, Zeft AS, Szer IS, Ringold S, Brunner HI, Schanberg LE, et al. Trial of early aggressive therapy in polyarticular juvenile idiopathic arthritis. Arthritis Rheum. 2011;64(6):2012-21.
18. Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, Van ZD, Kerstens PJ, Hazes JM, Zwinderman AH, Peeters AJ, de Jonge-Bok JM, Mallee C, et al. Comparison of treatment strategies in early rheumatoid arthritis: a randomized trial. Ann Intern Med. 2007;146(6):406-15.
19. Albers HM, Wessels JA, van der Straaten RJ, Brinkman DM, Suijlekom-Smit LW, Kamphuis SS, Girschick HJ, Wouters C, Schilham MW, le CS, et al. Time to treatment as an important factor for the response to methotrexate in juvenile idiopathic arthritis. Arthritis Rheum. 2009;61(1):46-51.
20. Bartoli M, Taro M, Magni-Manzoni S, Pistorio A, Traverso F, Viola S, Magnani A, Gasparini C, Martini A, Ravelli A. The magnitude of early response to methotrexate therapy predicts long-term outcome of patients with juvenile idiopathic arthritis. Ann Rheum Dis. 2008;67(3):370-4.
21. Oen K, Duffy CM, Tse SM, Ramsey S, Ellsworth J, Chedeville G, Chetaille AL, Saint-Cyr C, Cabral DA, Spiegel LR, et al. Early outcomes and improvement of patients with juvenile idiopathic arthritis enrolled in a Canadian multicenter inception cohort. Arthritis Care Res (Hoboken ). 2010;62(4):527-36.
22. Schmeling H, Horneff G. Etanercept and uveitis in patients with juvenile idiopathic arthritis. Rheumatology (Oxford). 2005;44(8):1008-11.
23. Saurenmann RK, Levin AV, Feldman BM, Laxer RM, Schneider R, Silverman ED. Risk of new-onset uveitis in patients with juvenile idiopathic arthritis treated with anti-TNFalpha agents. J Pediatr. 2006;149(6):833-6.
24. Anink J, Otten MH, Gorter SL, Prince FH, van Rossum MA, van den Berg JM, van Pelt PA, Kamphuis S, Brinkman DM, Swen WA, et al. Treatment choices of paediatric rheumatologists for juvenile idiopathic arthritis: etanercept or adalimumab? Rheumatology (Oxford). 2013;52(9):1674-9.
25. Tynjala P, Lindahl P, Honkanen V, Lahdenne P, Kotaniemi K. Infliximab and etanercept in the treatment of chronic uveitis associated with refractory juvenile idiopathic arthritis. Ann Rheum Dis. 2007;66(4):548-50.
26. Wendling D, Paccou J, Berthelot JM, Flipo RM, Guillaume-Czitrom S, Prati C, Dernis E, Direz G, Ferrazzi V, Ristori JM. New onset of uveitis during anti-tumor necrosis factor treatment for rheumatic diseases. Semin Arthritis Rheum. 2011;41(3):503-10.
27. Giannini EH, Ruperto N, Ravelli A, Lovell DJ, Felson DT, Martini A. Preliminary definition of improvement in juvenile arthritis 14. Arthritis Rheum. 1997;40(7):1202-9.
28. Wallace CA, Ruperto N, Giannini E. Preliminary criteria for clinical remission for select categories of juvenile idiopathic arthritis. J Rheumatol. 2004;31(11):2290-4.
29. Wallace CA, Giannini EH, Huang B, Itert L, Ruperto N. American College of Rheumatology provisional criteria for defining clinical inactive disease in select categories of juvenile idiopathic arthritis. Arthritis Care Res (Hoboken ). 2011;63(7):929-36.
30. Prince FH, Twilt M, ten CR, van Rossum MA, Armbrust W, Hoppenreijs EP, van Santen-Hoeufft M, Koopman-Keemink Y, Wulffraat NM, van Suijlekom-Smit LW. Long-term follow-up on effectiveness and safety of etanercept in juvenile idiopathic arthritis: the Dutch national register. Ann Rheum Dis. 2009;68(5):635-41.
31. Consolaro A, Ruperto N, Bazso A, Pistorio A, Magni-Manzoni S, Filocamo G, Malattia C, Viola S, Martini A, Ravelli A. Development and validation of a composite disease activity score for juvenile idiopathic arthritis. Arthritis Rheum. 2009;61(5):658-66.